SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience.

Isitt, C; Cosgrove, CA; Ramsay, ME; Ladhani, SN (2020) Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. ISSN 1468-2044 https://doi.org/10.1136/archdischild-2019-318047
SGUL Authors: Ladhani, Shamez Nizarali

[img] Microsoft Word (.docx) Published Version
Available under License ["licenses_description_publisher" not defined].

Download (615kB)

Abstract

Meningococcal disease remains one of the most feared infectious diseases worldwide because of its sudden onset, rapid progression and high case fatality rates, while survivors are often left with severe long-term sequelae. Young children have the highest incidence of invasive meningococcal disease (IMD), and nearly all cases in the UK, as in most of Europe and many other industrialised countries, are due to group B meningococci (MenB). The licensure of a broad-coverage, recombinant protein-based MenB vaccine (4CMenB) in 2013 was, therefore, heralded a major breakthrough in the fight against IMD. This vaccine was, however, licensed on immunogenicity and reactogenicity studies only, raising uncertainties about field effectiveness, long-term safety and antibody persistence. In 2015, the UK became the first country to implement 4CMenB into the national infant immunisation schedule and, since then, several countries have followed suit. Seven years after licensure, a wealth of real-world data has emerged to confirm 4CMenB effectiveness, along with large-scale safety data, duration of protection in different age groups, successful strategies to reduce vaccine reactogenicity, impact on carriage in adolescents and the potential for 4CMenB to protect against other meningococcal serogroups and against gonorrhoea. A number of questions, however, remain unanswered, including the investigation and management of vaccine-associated fever in infants, as well as disease severity and assessment of breakthrough cases in immunised children. Increasing use of 4CMenB will provide answers in due course. We now have vaccines against all the major serogroups causing IMD worldwide. Next-generation and combination vaccines against multiple serogroups look very promising.

Item Type: Article
Additional Information: This article has been accepted for publication in Archives of Disease in Childhood, 2020 following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/archdischild-2019-318047. © Author(s) (or their employer(s)) 2020.
Keywords: immunisation, infectious diseases, Pediatrics, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, 1117 Public Health and Health Services
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Arch Dis Child
ISSN: 1468-2044
Language: eng
Dates:
DateEvent
6 February 2020Published Online
15 January 2020Accepted
Publisher License: Publisher's own licence
PubMed ID: 32029437
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111659
Publisher's version: https://doi.org/10.1136/archdischild-2019-318047

Actions (login required)

Edit Item Edit Item